Sanofi (SNY) Assets Average (2018 - 2026)
Sanofi's (SNY) quarterly Assets Average came in at $149.9 billion in Q2 2026, up 7.04% year-over-year from $140.1 billion in Q2 2025, and up 0.81% quarter-over-quarter from $148.7 billion in Q1 2026.
Analysis
Sanofi (SNY) Assets Average (2018 - 2026) Analysis & Trends
Sanofi has disclosed Assets Average across 3 years of filings, most recently posting $149.9 billion for Q2 2026.
- In Q2 2026, Assets Average rose 7.04% year-over-year to $149.9 billion; the TTM figure through Jun 2026 stood at $149.9 billion (up 7.04% YoY), while the FY2024 annual figure was $140.3 billion, up 3.76% from the prior year.
- Assets Average came in at $149.9 billion for Q2 2026 at Sanofi, up from $148.7 billion in the prior quarter.
- In the past five years, Assets Average ranged from a high of $149.9 billion in Q2 2026 to a low of $140.1 billion in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 120.28 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | 204.57 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | 149.95 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | 3.29 Bn |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | 7.61 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | 6.97 Bn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | 5.13 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 149.95 Bn |
| Mar 31, 2026 | 148.75 Bn |
| Dec 31, 2025 | 149.67 Bn |
| Sep 30, 2025 | 146.59 Bn |
| Jun 30, 2025 | 140.09 Bn |
| Mar 31, 2025 | 140.32 Bn |
| Dec 31, 2018 | 64.51 Bn |
| Sep 30, 2018 | 68.22 Bn |
| Jun 30, 2018 | 135.89 Bn |
| Mar 31, 2018 | 127.35 Bn |